Indegene Limited (NSE:INDGN)
India · Delayed Price · Currency is INR | Market Cap | 119.94B -5.9% |
| Revenue (ttm) | 32.63B +18.4% |
| Net Income | 4.39B +14.4% |
| EPS | 18.21 +11.5% |
| Shares Out | 240.01M |
| PE Ratio | 27.44 |
| Forward PE | 24.00 |
| Dividend | 2.00 (0.40%) |
| Ex-Dividend Date | n/a |
| Volume | 564,596 |
| Average Volume | 251,547 |
| Open | 481.10 |
| Previous Close | 495.45 |
| Day's Range | 481.10 - 508.15 |
| 52-Week Range | 414.00 - 632.90 |
| Beta | n/a |
| RSI | 59.35 |
| Earnings Date | Apr 29, 2026 |
About Indegene
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technolo... [Read more]
Financial Performance
In fiscal year 2025, Indegene's revenue was 28.39 billion, an increase of 9.64% compared to the previous year's 25.90 billion. Earnings were 4.07 billion, an increase of 20.79%.
Financial StatementsNews
Indegene Transcript: Q4 25/26
Record revenue and strong cash flow marked FY 2026, with GenAI-led solutions driving growth across both top and expanding customer segments. Margin recovery and multi-year growth are expected as recent investments and acquisitions scale, supported by a robust industry outlook.
Indegene Transcript: Q3 25/26
Q3 FY2026 delivered 30.8% year-on-year revenue growth and 18.5% adjusted EBITDA margin, driven by large AI-enabled deal wins and successful BioPharm integration. Management expects margins to improve and strong cash flows to continue as synergies materialize.
Indegene Transcript: Q2 25/26
Q2 revenue grew 17.1% YoY with strong deal wins and robust pipeline, despite near-term margin compression from investments in GenAI and acquisitions. Industry headwinds from U.S. policy changes are manageable, and management expects margins to recover as growth accelerates.
Indegene Transcript: Q1 25/26
Q1 FY2026 saw 12.5% year-over-year revenue growth, stable 20.2% EBITDA margin, and strong cash reserves. Enterprise segments drove growth, while Brand Activation faced project deferrals. AI initiatives and Tectonic are gaining traction, with a robust deal pipeline and M&A focus.
Indegene Transcript: Q4 24/25
Q4 and FY25 saw solid revenue and PAT growth, with strong cash reserves and a 100% dividend declared. AI and M&A remain strategic priorities amid macro uncertainties, while margins are stable and recurring revenues drive performance.
Indegene Transcript: Q3 24/25
Q3 FY25 saw 4.9% sequential and 7% year-over-year revenue growth, with EBITDA up 18.5% and PAT up 19.6%. Major client renewals, new mid-tier client wins, and improved margins position the company for continued growth amid cautious industry recovery.
Indegene Transcript: Q2 24/25
Q2 FY25 revenue grew 8.8% year-on-year, led by enterprise segments and stabilized top accounts. EBITDA margin was 18.4%, impacted by wage hikes but offset by productivity gains. Management expects robust H2 growth, with strong cash reserves and ongoing M&A activity.
Indegene Transcript: Q1 24/25
Q1 FY25 saw 11.4% revenue growth and 28.3% PAT growth year-over-year, despite temporary headwinds from two major clients. The company is now debt-free, maintains strong margins, and expects a robust H2 and medium-term growth, supported by a healthy pipeline and recent strategic wins.